Linezolid IV, Oral | Right Decisions

Right Decisions
Antimicrobial prescribing: NHS Grampian, Orkney & Shetland
Back
Protected (Alert) Policy
Linezolid IV, Oral

Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Permitted indications

May be used for the following indications:

Staphylococcal pneumonia (e.g. post influenza infection) in patients with penicillin allergy.
For MRSA infections post-vascular surgery where an oral option is necessary.

Otherwise, only on the advice of a Medical Microbiologist or Infection Specialist for:

Restricted indications including infections due to proven glycopeptide-insensitive Staphylococcus aureus (GISA) or vancomycin-resistant enterococcus (VRE) (currently uncommon).
Enabling IV/oral switch from IV vancomycin to oral linezolid (when patient discharge is possible and continuation treatment using combination, e.g. rifampicin/trimethoprim is inappropriate).
Poor IV access and a glycopeptide is indicated.
Use in out-patient antibiotic therapy for skin and soft tissue infections as an alternative to IV teicoplanin.
Rare cases of (proven) hypersensitivity/allergy to the glycopeptides.

For all other indications contact the duty Medical Microbiologist.

Not licensed for use in children.